Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Xinliang Zhou is active.

Publication


Featured researches published by Xinliang Zhou.


Cancer Letters | 2011

Melanoma-associated antigen genes – An update

Meixiang Sang; Lifang Wang; Chunyan Ding; Xinliang Zhou; Bin Wang; Ling Wang; Yishui Lian; Baoen Shan

To date, dozens of melanoma-associated antigens (MAGE) have been identified. Based on the differences in tissue-specific gene expression and gene structure, the MAGE family has been divided into two big subfamilies: MAGE-I and MAGE-II. MAGE-I genes were identified as a group of highly attractive targets for cancer immunotherapy because of their wide expression in a variety of malignant tumors but silent in normal adult cells except germ-line cells lacking human leukocyte antigen (HLA) expression. However, little is known regarding the functions of MAGE family members in cell activities. In this review, we briefly described the classification of MAGE family members and their expression pattern in cancer. We also summarized the mechanism of MAGE activation and the functions of MAGE family members in cell cycle progression and apoptosis. We also discussed what is known of immunotherapy targeting MAGE family.


Vaccine | 2011

MAGE-A family: attractive targets for cancer immunotherapy.

Meixiang Sang; Yishui Lian; Xinliang Zhou; Baoen Shan

The melonoma-associated antigens family A (MAGE-A) belongs to cancer/testis antigens (CTA) that are expressed in a wide variety of malignant tumors but not in normal adult tissues except for testis. Interestingly, germ cells do not express MHC class I antigen, implying that these gene products should be ideal targets for cancer immunotherapy. The strict tumor-specific expression of MAGE-As has led to several immunotherapeutic trials targeting some of these proteins. In this review, we briefly described the expression and activation mechanism of MAGE-As in cancer. We also summarized the biological functions of MAGE-As in cell progress and the progress of the cancer immunotherapy targeting MAGE-A family.


Medical Oncology | 2015

The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression.

Xinliang Zhou; Yudong Wang; Baoen Shan; Jing Han; Haifeng Zhu; Yalei Lv; Xiaojie Fan; Meixiang Sang; Xian De Liu; Wei Liu

AbstractGastric cancer is the fourth most common malignancy in the world. Although microRNA-200 (miR-200) family members are thought to play roles in tumorigenesis, their functions in carcinogenesis are tumor specific, and the underlying mechanism of action still remains elusive. Few studies to date have addressed the dysregulation and function of miR-200 family members in gastric cancer progression. Here, we report that the miR-200 family members, miR-200c and miR-141, were significantly downregulated in gastric cancer specimens and gastric cancer cell lines. Importantly, on clinical samples, the expression of miR-200c and miR-141 was inversely correlated with TNM stage, tumor invasion depth (T), tumor embolus and disease-free survival. Wound-healing assay results showed that co-transfected miR-200c/141 could inhibit the migration and invasion capability of the gastric cell line SGC-7901. We also found that miR-200c and miR-141 directly targeted zinc finger E-box-binding homeobox 1/2 (ZEB1/2) and upregulated E-cadherin expression. In specimens from gastric cancer patients, reduced expression of miR-200c/141 was associated with increased expression of ZEB1 and/or ZEB2. In addition, the downregulation of miR-200c and miR-141 was found to be due to a highly methylated CpG island located upstream of their genomic sequence and/or upregulated TGF-β signaling. Treatment with the chemotherapeutic agent decitabine, a known DNA methyltransferase inhibitor, increased miR-200c/141 expression and ameliorated decreased expression of miR-200c/141 induced by TGF-β in SGC-7901 cells. Our study revealed that miR-200c/141 was downregulated by CpG island methylation and TGF-β signaling, which decreased ZEB1/2 expression and increased E-cadherin expression to inhibit migration and invasion of gastric cancer cells and provides powerful evidence for the application of decitabine in gastric cancer treatment.


Biomarkers | 2014

Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer

Meixiang Sang; Xiaohua Wu; Xiaojie Fan; Meijie Sang; Xinliang Zhou; Nan Zhou

Abstract Ovarian cancer is a leading cause of death among gynecologic malignancies. In this study, we reported the expression of melanoma-associated antigens A (MAGE-A) genes in peripheral blood from 80 patients with ovarian cancer and 30 healthy donors. MAGE-As expression was associated with the factors indicating poor prognosis. The expressions of MAGE-As and each individual MAGE-A genes were also associated with low overall survival of patients with ovarian cancer. Our results suggested MAGE-A genes may have the potential to be surveillance markers for the detection of circulating tumor cells and represent a poor prognosis for patients with ovarian cancer.


Molecular Biology Reports | 2014

LIM-domain-only proteins: multifunctional nuclear transcription coregulators that interacts with diverse proteins.

Meixiang Sang; Li Ma; Meijie Sang; Xinliang Zhou; Wei Gao; Cuizhi Geng

The LIM-only subclass of LIM proteins is a family of nuclear transcription co-regulators that are characterized by the exclusive presence of two tandem LIM domains and no other functional domains. To date, four LIM-domain-only (LMO) proteins (LMO1-LMO4) have been identified. They regulate gene transcription by functioning as “linker” or “scaffolding” proteins with a remarkable potential to mediate protein–protein interactions. These proteins play important roles in cell fate determination, cell growth and differentiation, tissues patterning, and organ development. In this review, we briefly described the functions of LMO proteins in the organ development and diseases. We also summarized the interaction proteins of each LMO family member, which may contribute to elucidating the functions of these mysterious and important linker proteins.


Molecular Medicine Reports | 2015

Downregulation of microRNA‑33a promotes cyclin‑dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation

Yudong Wang; Xinliang Zhou; Baoen Shan; Jing Han; Feifei Wang; Xiaojie Fan; Yalei Lv; Liang Shuo Chang; Wei Liu

Although microRNA-33 (miR-33) family members are known to be involved in the regulation and balancing of cholesterol metabolism, fatty acid oxidation and insulin signaling, their functions in carcinogenesis are controversial and the underlying mechanisms have remained elusive. Gastric cancer is the fourth most common malignancy in the world; however, the dysregulation and function of miR-33 family members in gastric cancer have not been extensively studied. The present study reported that a miR-33 family member, miR-33a, was significantly downregulated in gastric cancer tissues and gastric cancer cell lines. Of note, the expression of miR-33a was inversely correlated with pathological differentiation and metastasis as well as gastric cancer biomarker CA199. A cell-counting kit-8 assay showed that transfection of the SGC-7901 gastric cell line with miR-33a-overexpression plasmid inhibited the capability of the cells to proliferate. Furthermore, overexpression of miR-33a led to cell cycle arrest of SGC-7901 cells in G1 phase. In addition, a luciferase reporter assay showed that miR-33a directly targeted cyclin-dependent kinase 6 (CDK6), cyclin D1 (CCND1) and serine/threonine kinase PIM-1. In gastric cancer specimens, the reduced expression of miR-33a was associated with increased expression of CDK-6, CCND1 and PIM1. However, only PIM1 expression was significantly increased in cancer tissues compared with that in their adjacent tissues. The present study revealed that miR-33a was downregulated in gastric cancer tissues and cell lines, while forced overexpression of miR-33a decreased CDK-6, CCND1 and PIM1 expression to inhibit gastric cancer cell proliferation by causing G1 phase arrest. miR-33a overexpression may therefore resemble an efficient strategy for gastric cancer therapy.


Cancer Gene Therapy | 2018

miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer

Xinliang Zhou; Xinyi Men; Riyang Zhao; Jing Han; Zhisong Fan; Yudong Wang; Yalei Lv; Jing Zuo; Lianmei Zhao; Meixiang Sang; Xian De Liu; Baoen Shan

Gastric cancer is the fifth most common malignancy in the world, with Eastern Asia as one of areas with the highest incidence rates. Trastuzumab, a HER2-targeting antibody, combined with chemotherapy has been successfully employed for the gastric cancer patients with HER2 overexpression/amplification. However, trastuzumab resistance is a major problem in clinical practice. Here we observed that the trastuzumab-resistant gastric cancer cell line NCI-N87/TR expressed high levels of epithelial–mesenchymal transition factors and demonstrated increased migration and invasion capability compared with NCI-N87 cells. Downregulated E-cadherin and increased N-cadherin, TGF-β, ZEB1, ZEB2, TWIST1, and Snail were detected in NCI-N87/TR cells. We also found that miR-200c was downregulated in NCI-N87/TR cells compared with parental cells NCI-87 by qRT-PCR. Treatment with TGF-β downregulated the expression of miR-200c and upregulated ZEB2, and significantly decreased the trastuzumab sensitivity of NCI-N87 cells. miR-200c restored trastuzumab sensitivity and inhibited migration and invasion through suppressing ZEB1 and ZEB2. In summary, TGF-β/ZEB2 axis plays an encouraging role in trastuzumab resistance of gastric cancer, while miR-200c overexpression downregulates ZEB1/ZEB2 and resensitizes drugs resistance. Our findings might provide a potential therapeutic strategy for trastuzumab resistance of gastric cancer.


Gastroenterology Research and Practice | 2017

Effects of Combined Simultaneous and Sequential Endostar and Cisplatin Treatment in a Mice Model of Gastric Cancer Peritoneal Metastases

Lin Jia; Shuguang Ren; Tao Li; Jianing Wu; Xinliang Zhou; Yan Zhang; Jianhua Wu; Wei Liu

Objective. Aimed to study the effects of endostar and cisplatin using an in vivo imaging system (IVIS) in a model of peritoneal metastasis of gastric cancer. Methods. NUGC-4 gastric cancer cells transfected with luciferase gene (NUGC-4-Luc) were injected i.p. into nude mice. One week later, mice were randomly injected i.p.: group 1, cisplatin (d1–3) + endostar (d4–7); group 2, endostar (d1–4) + cisplatin (d5–7); group 3, endostar + cisplatin d1, 4, and 7; group 4, saline for two weeks. One week after the final administration, mice were sacrificed. Bioluminescent data, microvessel density (MVD), and lymphatic vessel density (LVD) were analyzed. Results. Among the four groups, there were no significant differences in the weights and in the number of cancer cell photons on days 1 and 8 (P > 0.05). On day 15, the numbers in groups 3 and 1 were less than that in group 2 (P < 0.05). On day 21, group 3 was significantly less than group 2 (P < 0.05). MVD of group 4 was less than that of groups 1 and 2 (P < 0.01). There was no significant difference between groups 2 and 3 (P > 0.05) or in LVD number among the four groups (P > 0.05). Conclusions. IVIS® was more useful than weight, volume of ascites, and number of peritoneal nodules. The simultaneous group was superior to sequential groups in killing cancer cells and inhibiting vascular endothelium. Cisplatin-endostar was superior to endostar-cisplatin in killing cancer cells, while the latter in inhibiting peritoneal vascular endothelium.


Journal of Cancer Research and Clinical Oncology | 2012

Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study

Yishui Lian; Meixiang Sang; Chunyan Ding; Xinliang Zhou; Xiaojie Fan; Yingying Xu; Weihua Lü; Baoen Shan


Life Sciences | 2012

LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53.

Xinliang Zhou; Meixiang Sang; Wei Liu; Wei Gao; Enhong Xing; Weihua Lü; Yingying Xu; Xiaojie Fan; Shaowu Jing; Baoen Shan

Collaboration


Dive into the Xinliang Zhou's collaboration.

Top Co-Authors

Avatar

Meixiang Sang

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Baoen Shan

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Wei Liu

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Xiaojie Fan

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Yudong Wang

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Jing Han

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Yalei Lv

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Yishui Lian

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Chunyan Ding

Hebei Medical University

View shared research outputs
Top Co-Authors

Avatar

Jing Zuo

Hebei Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge